Boston Scientific Corporation has announced its clinical data that will be featured at the upcoming North American Neuromodulation Society (NANS) annual meeting (18–21 January, Las Vegas, USA). A total of 19 abstracts from the company’s chronic pain and deep brain stimulation (DBS) portfolios have been accepted, including a late-breaking presentation on the WaveWriter Alpha spinal cord stimulation (SCS) system.
The SOLIS randomised controlled trial (RCT) is evaluating the use of the WaveWriter SCS systems for the treatment of non-surgical back pain (NSBP) when compared to conventional medical management (CMM). A late-breaking presentation at NANS 2024 will review one-year outcomes of the trial.
“Boston Scientific is advancing the treatment paradigms for people living with chronic pain or movement disorders,” said Jim Cassidy, president, Neuromodulation, Boston Scientific. “Data included at this year’s NANS meeting reflect the breadth and depth of meaningful clinical evidence supporting our technologies, and our commitment to deliver innovative solutions for physicians and their patients.”
Additional data being presented on the Boston Scientific portfolio include clinical outcomes on Fast-Acting Sub-perception Therapy (FAST) with SCS, and real-world outcomes in essential tremor using DBS. Long-term outcomes on SCS for diabetic peripheral neuropathy (DPN) that support the most recent indication expansion for this condition will also be presented, as per a Boston Scientific press release.
A complete list of Boston Scientific’s clinical and scientific data presentations at NANS 2024 can be viewed here.
